Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I
Research output: Contribution to journal › Journal article › Research › peer-review
Although DNA-based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumour antigens are weak and fail to generate a vigorous immune response in tumour-bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune-activating genes to the tumour antigen sequence. In this work, we converted a model non-immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage coat protein III gene. Vaccination with a DNA construct encoding the domain I fusion generated antigen-specific T helper 1-type cellular immune responses. These results demonstrate that the incorporation of protein III into a DNA vaccine formulation can modulate the gene-mediated immune response and may thus provide a strategy for improving its therapeutic effect.
Original language | English |
---|---|
Journal | Immunology |
Volume | 117 |
Issue number | 4 |
Pages (from-to) | 502-6 |
Number of pages | 5 |
ISSN | 0019-2805 |
DOIs | |
Publication status | Published - Apr 2006 |
Externally published | Yes |
- Adjuvants, Immunologic, Animals, Antigens, Neoplasm/immunology, Cancer Vaccines/immunology, Capsid Proteins, Cytokines/biosynthesis, DNA-Binding Proteins/immunology, Female, Immunity, Cellular, Immunoglobulin G/biosynthesis, Immunoglobulin Variable Region/immunology, Mice, Mice, Inbred BALB C, Recombinant Fusion Proteins/immunology, Th1 Cells/immunology, Vaccination, Vaccines, DNA/immunology, Viral Fusion Proteins/immunology
Research areas
ID: 200572160